Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

3,052.45INR
12:32pm IST
Change (% chg)

Rs27.30 (+0.90%)
Prev Close
Rs3,025.15
Open
Rs3,020.00
Day's High
Rs3,072.00
Day's Low
Rs3,020.00
Volume
113,769
Avg. Vol
422,547
52-wk High
Rs4,386.60
52-wk Low
Rs2,750.05

REDY.NS

Chart for REDY.NS

About

Dr. Reddy's Laboratories Limited is an integrated global pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Global Generics segment consists of its business of manufacturing and... (more)

Overall

Beta: 0.35
Market Cap(Mil.): Rs516,700.00
Shares Outstanding(Mil.): 170.54
Dividend: 20.00
Yield (%): 0.66

Financials

  REDY.NS Industry Sector
P/E (TTM): 147.30 34.43 35.43
EPS (TTM): 20.57 -- --
ROI: -- 13.73 13.09
ROE: -- 14.71 14.22

India's Dr Reddy's falls on weak results, Deutsche Bank forecast cut

** India's second largest drugmaker on Thursday posted a near 86 pct slump in March-quarter profit

13 May 2016

BUZZ-India's Dr Reddy's rises on FDA approval for anti-nausea drug

** Dr Reddy's Laboratories rises as much as 3.5 pct, among top pct gainers on S&P BSE Healthcare index

03 Mar 2016

BUZZ-India's Dr. Reddy's rises for 2nd day as investors cheer buyback

** Dr. Reddy's Laboratories rises as much as 5.65 pct to 3,128 rupees, posts biggest intraday percentage gain in nearly 4 months

18 Feb 2016

MEDIA-Torrent Pharma, Dr. Reddy's, Aurobindo, Cipla, Lupin in race to buy Sagent Pharma - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy (Bengaluru newsroom)

25 Jan 2016

BUZZ-India's Dr. Reddy's rises on Nexium generic relaunch in U.S.

** Dr. Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, rises as much as 2.31 pct to its highest level since Dec 7

30 Dec 2015

BUZZ-India's Dr Reddy's slumps; US FDA releases details of warning letter

** US FDA releases details of warning letter (http://1.usa.gov/1QIDDeg)

26 Nov 2015

Earnings vs. Estimates